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ABSTRACT 
Emergence of drug-resistant strains of Plasmodium has recently led to increased efforts to 
discover and develop new antimalarial drugs both for the prophylaxis and treatment of 
malaria infection. The present study was conducted to evaluate the antiplasmodial activity 
of novel hydroxamic acid derivative against Plasmodium falciparum 3D7 strain and the 
wild type isolate from malaria infected patients. Chloroquine-sensitive P. falciparum 3D7 
was grown in vitro in O+ human red blood cells in RPMI 1640 medium supplemented 
with 10% heat inactivated AB human serum, 25 mM HEPES buffer, 50 µg/ml penicillin 
and 50 µg/ml streptomycin under an atmosphere of 90% N2, 5% O2 and 5% CO2. Serially 
diluted drugs were placed in the wells of 96 well micro titre plates and incubated with 
aliquots of parasite culture medium containing asynchronized rings at a parasitemia of 
0.2% and a haematocrit of 4%. For the ex vivo assay, aliquots of the washed infected red 
blood cells in complete medium were incubated with varying concentrations of the drugs. 
The parasitemia for both assays were determined microscopically using Giemsa-stained 
smears. Chloroquine and artemisinin used as the positive controls as well as the drug-free 
negative control were all assayed in duplicates simultaneously with the test compound 
(OA4). Results from the half maximal inhibitory concentrations (IC50) analyses showed 
the in vitro and ex vivo IC50 values of OA4 to be 28200 nM and 154.2 nM respectively. 
OA4 lowered the parasitemia across all the drug-treated wells when compared to the 
drug-free negative control wells. The result from the erythrocyte stabilization assay 
revealed that OA4 did not induce any alteration on the morphology of red blood cells. In 
conclusion, these results demonstrated that the hydroxamic acid derivative OA4 could be 
a promising antimalarial drug candidate and is therefore a useful hit compound for further 
medicinal chemistry optimization. 
Keywords: Malaria, P. falciparum, hydroxamates, drug sensitivity, cell morphology 
 
 
 
 
